Related Experiment Video
Updated: Jan 9, 2026

07:25
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
13.7K
Two Cases of Metastatic Castration-Resistant Prostate Cancer With Long-Term Survival Treated With Abiraterone
Minami Une1, Shinya Yamamoto1, Honoka Fuse1
1Department of Urology Nishitokyo Chuo General Hospital Tokyo Japan.
Clinical Case Reports
|December 8, 2025
Abstract
None:
We report two cases of metastatic castration-resistant prostate cancer (mCRPC) with long-term survival following treatment with abiraterone. Despite the generally temporary efficacy of abiraterone, both patients remained progression-free for over 5 years, suggesting that some mCRPC patients may achieve durable responses with abiraterone.
Related Concept Videos
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Cancer Survival Analysis
630
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
630

